Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations
Scope
As issued by the authors
CV toxicity of cancer therapy: 1) cardioprotection (primary prevention of cancer therapy-related CV toxicity); 2) surveillance (monitoring for CV toxicity during cancer therapy); 3) permissive cardiotoxicity (informed continuation of cancer therapy despite CV toxicity, with mitigating CV treatments); 4) special considerations (invasive management of severe CVD in patients treated for advanced cancer; drug-drug interactions in cardio-oncology); gaps in evidence
Original publication
Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations. JACC CardioOncol. Published 5 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →